Koninklijke Phil Stock Price, News & Analysis

Philips (NYSE: PHG) has successfully completed the acquisition of BioTelemetry (NASDAQ: BEAT), creating a global leader in patient care management solutions for hospitals and homes. The acquisition consolidates BioTelemetry's $450 million sales and its extensive remote cardiac monitoring services into Philips’ Connected Care business segment. The deal is expected to yield nominal sales growth and positive EBITA margins in 2021, with ambitions for double-digit growth and over 20% EBITA margin by 2025.

Royal Philips has completed its tender offer to acquire all outstanding shares of BioTelemetry for USD 72.00 per share in cash. The Offer, which expired on February 9, 2021, resulted in 27,182,062 shares being tendered, representing approximately 78.96% of BioTelemetry's outstanding shares. Following the merger, BioTelemetry will become a wholly owned subsidiary of Philips, with shares converting into cash payments, and will be delisted from NASDAQ.

Royal Philips (NYSE: PHG) has formed a 5-year strategic partnership with the Dutch SAZ group, comprising 28 hospitals, to advance connected care. This collaboration focuses on enhancing patient monitoring and self-management, incorporating Philips' technologies.

The initiative aims to shift care closer to patients' homes, reduce ICU readmissions, and improve health outcomes through early detection. Notably, projects in 2021 will include in-hospital applications and home monitoring for chronic conditions, leveraging the Engage platform for patient data management.

Royal Philips has launched the Philips Medical Tablet in North America, Europe, and Japan to facilitate remote patient monitoring during emergencies such as the COVID-19 pandemic. This portable device integrates with the IntelliVue XDS software, allowing clinicians to monitor multiple patients without being tied to central stations. The solution aims to improve workflows amidst increased patient volume and PPE shortages, enhancing safety for both patients and healthcare providers. With a focus on rapid deployment, the tablet is positioned to support hospitals adapting to the pandemic's challenges.

Philips Espresso has partnered with actor Justin Baldoni to encourage healthy daily routines through an Instagram giveaway. The contest, running from December 10 to December 12, will reward five winners with a Philips Espresso 3200 with LatteGo and $1,000 each. Participants share stories on Baldoni's Instagram post about someone in need of support. A study reveals that 59% of adults achieved more than expected in 2020, with coffee drinkers 73% more likely to succeed. Philips aims to inspire positive changes as people look forward to 2021.

Royal Philips (NYSE: PHG) announced a technical failure experienced by Euronext, which is affecting the accurate closing price for Philips shares on October 19, 2020. The company indicated that the closing price is expected to be close to EUR 42.305, which reflects the last recorded price during regular trading. Euronext is actively working to resolve this issue. Philips, a leader in health technology, reported sales of EUR 19.5 billion in 2019 and has a global workforce of approximately 81,000 employees.

Philips reported Q3 sales of EUR 5.0 billion, reflecting a 10% comparable sales growth, while income from continuing operations rose to EUR 341 million. The company's Adjusted EBITA margin improved by 300 basis points to 15.4%, and operating cash flow increased to EUR 770 million. Although comparable order intake declined by 18%, it increased by 3% when excluding a partial ventilator contract termination with HHS. Philips aims for average annual comparable sales growth of 5-6% from 2021–2025.

The DEFINE PCI study results reveal that iFR co-registration enhances patient outcomes post-PCI by identifying and treating residual ischemia more effectively than conventional angiography. Findings showed that 24% of patients experienced residual ischemia despite successful PCI, with 82% potentially treatable. Patients with optimal post-PCI iFR (≥0.95) had 68% fewer clinical events at one year, indicating significant improvements in survival and reduced angina. Philips continues to innovate with tools like OmniWire and the Azurion platform to advance interventional therapy.